Antalium

Antalium is a French biotechnology company dedicated to developing innovative treatments for chronic pain, with a specific focus on neuropathic pain. The company's lead program, ANT-01, is a first-in-class small molecule antagonist of the P2X4 receptor, which is a key driver of neuro-inflammation and pain sensitization. By targeting the peripheral nervous system, Antalium aims to provide a potent, non-opioid alternative for pain management that avoids central nervous system side effects and the risk of addiction. The company was founded by a team of experienced drug developers and is based in Montpellier, France. Antalium's research is built upon foundational discoveries regarding purinergic signaling in the context of chronic pain.